Delving into the Latest Updates on Beijing Jingfeng Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Urogenital Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

SCNA x VDCCs	1

考察中国健康受试者在空腹条件下单剂量静脉注射江苏迪赛诺制药有限公司生产，汇禹远和（海南）药业有限公司持有的地塞米松棕榈酸酯注射液（规格：1ml:4mg（以地塞米松棕榈酸酯计））与由Mitsubishi Tanabe Pharma Korea Co., Ltd.生产，Mitsubishi Tanabe Pharma Corporation持有的地塞米松棕榈酸酯注射液（规格：1ml:4mg（以地塞米松棕榈酸酯计））后的体内药代动力学特征，评价两制剂的生物等效性。

[Translation]

The in vivo pharmacokinetic characteristics of dexamethasone palmitate injection (Specification: 1 ml: 4 mg (as dexamethasone palmitate)) produced by Jiangsu Desano Pharmaceutical Co., Ltd. and owned by Huiyuyuanhe (Hainan) Pharmaceutical Co., Ltd. and dexamethasone palmitate injection (Specification: 1 ml: 4 mg (as dexamethasone palmitate)) produced by Mitsubishi Tanabe Pharma Korea Co., Ltd. and owned by Mitsubishi Tanabe Pharma Corporation were investigated in healthy Chinese subjects under fasting conditions, and the bioequivalence of the two preparations was evaluated.

Start Date26 Feb 2025

Sponsor / Collaborator

Huiyu Yuanhe (Hainan) Pharmaceutical Co., Ltd.

CTR20242689

/ CompletedPhase 1

评价利多卡因丙胺卡因气雾剂在中国健康女性受试者单次给药的药代动力学和安全性Ⅰ期研究

[Translation] A phase I study to evaluate the pharmacokinetics and safety of lidocaine prilocaine aerosol after a single dose in healthy Chinese female subjects

主要试验目的以Recordati Ireland Ltd.持证的利多卡因丙胺卡因气雾剂（商品名：Fortacin®）为参比制剂，以江苏柯菲平医药股份有限公司提供的利多卡因丙胺卡因气雾剂为受试制剂，进行中国健康女性受试者单次给药的药代动力学（PK）特征对比。次要试验目的评估参比制剂和受试制剂在中国健康女性受试者中单次给药的安全性。

[Translation]

Main purpose of the study Using the lidocaine prilocaine aerosol (trade name: Fortacin®) licensed by Recordati Ireland Ltd. as the reference preparation and the lidocaine prilocaine aerosol provided by Jiangsu Kefeiping Pharmaceutical Co., Ltd. as the test preparation, the pharmacokinetic (PK) characteristics of a single dose of Chinese healthy female subjects were compared. Secondary purpose of the study Evaluate the safety of a single dose of the reference preparation and the test preparation in Chinese healthy female subjects.

Start Date31 Jul 2024

Sponsor / Collaborator

Beijing Jingfeng Pharmaceutical Co. Ltd.

[+1]

CTR20242691

/ CompletedPhase 1

评价利多卡因丙胺卡因气雾剂在中国健康男性受试者单次给药的药代动力学和安全性Ⅰ期研究

[Translation] A phase I study to evaluate the pharmacokinetics and safety of lidocaine prilocaine aerosol after a single dose in healthy Chinese male subjects

主要目的以Recordati Ireland Ltd. 持证的利多卡因丙胺卡因气雾剂（商品名：Fortacin®）为参比制剂，以江苏柯菲平医药股份有限公司提供的利多卡因丙胺卡因气雾剂为受试制剂，进行中国健康男性受试者单次给药的药代动力学（PK）特征对比。次要目的以Recordati Ireland Ltd. 持证的利多卡因丙胺卡因气雾剂（商品名：Fortacin®）为参比制剂，以江苏柯菲平医药股份有限公司提供的利多卡因丙胺卡因气雾剂为受试制剂，评估参比制剂和受试制剂在中国健康男性受试者中单次给药的安全性。

[Translation]

Main purpose Using the lidocaine prilocaine aerosol (trade name: Fortacin®) licensed by Recordati Ireland Ltd. as the reference preparation and the lidocaine prilocaine aerosol provided by Jiangsu Kefeiping Pharmaceutical Co., Ltd. as the test preparation, the pharmacokinetic (PK) characteristics of a single dose in healthy Chinese male subjects were compared. Secondary purpose Using the lidocaine prilocaine aerosol (trade name: Fortacin®) licensed by Recordati Ireland Ltd. as the reference preparation and the lidocaine prilocaine aerosol provided by Jiangsu Kefeiping Pharmaceutical Co., Ltd. as the test preparation, the safety of the reference preparation and the test preparation in a single dose in healthy Chinese male subjects was evaluated.

Start Date31 Jul 2024

Sponsor / Collaborator

Beijing Jingfeng Pharmaceutical Co. Ltd.

[+1]

100 Clinical Results associated with Beijing Jingfeng Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Jingfeng Pharmaceutical Co. Ltd.

Login to view more data

1

Literatures (Medical) associated with Beijing Jingfeng Pharmaceutical Co. Ltd.

Guoji Yaoxue Yanjiu Zazhi

Nifedipine sustained-release matrix tablets based on direct compression: preparation, in vitro release, and in vivo evaluation in beagle dogs

Author: Zhang, Hong ; Wu, Juan ; Zhang, Xinzhong

Using the direct compression method, sustained-release matrix tablets for once daily administration of nifedipine were developed.The nifedipine tablets were prepared with hydroxypropyl Me cellulose as basic matrix material.The dissolution of nifedipine from the tablets was evaluated as a formulation that had a sustained release over 24 h.The pharmacokinetic parameters of beagle dogs were investigated by the HPLC-MS/MS method.Compared with control marketed tablets, the relative bioavailability of the test tablets was calculatedThe pharmacokinetic parameters of the test tablets were similar with the reference tablets, which indicated that the test tablets possessed excellent sustained-release performance.Relative bioavailability of the test tablets to control was (100.9 ± 12.4)%.Statistics anal. showed that the release percentage of nifedipine from tablets in vitro was related to the drug absorption rate in vivo.The test nifedipine tablets could be an ideal 24 h sustained-release formulation.

100 Deals associated with Beijing Jingfeng Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Jingfeng Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data